HealthEcon is one of the most experienced healthcare consulting companies in Europe. We are based in Basel, Switzerland, with more than 1100 projects completed since our establishment in 1981. We mainly provide consultation services on pharmaceuticals for the leading European markets
Leadership Team
Dr. Pascale Holzerny
Team Lead HTA / Oncology & Epidemiology• Pharmacist. Phd at Novartis Pharma in Basel, joined HealthEcon in 2012
• 15 years of experience in strategy and tactics of HTA.
• Contributed and led the compilation of 71 AMNOG dossiers, mostly for oncology drugs and rare diseases.
• Project lead for HealthEcon’s EU-HTA projects.
• As a native French and German speaker, also leads the compilation of reimbursement dossiers for Switzerland.
Dr. Stephan Ruckdäschel
Managing Director• Economist. In 2000, joined Pfizer in Outcomes Research and Disease Management.
• Joined HealthEcon in 2005:
* led the company’s development into a widely recognized HTA specialist organization,
* compiled and lead a multitude of HTAs, value and reimbursement dossiers as well as scenario analysis,
* built, trained, and led (EU-)HTA teams and
* established operational readiness for EU HTA, including JSC and JCA.
• 26 years of experience in development and implementation of tailored solutions for pharmaceutical clients.
Projects
Since our establishment in 1981, we have completed more than 1100 projects for over 200 clients. We have supported European governments, associations, sickness funds and pharmaceutical companies. Our clients include most of the global top 20 pharmaceutical companies, as well as small and medium-sized biotech companies.
Reference are available upon request.
Publications
-
Neue Züricher Zeitung
Schuhmacher P, Ruckdäschel S (2018)
Dunkelkammer Medikamentenpreise
-
Gesundheitsökonomie und Qualitätsmanagement
Holzerny P, Werner S, Rouf J (2018)
Sind G-BA Beschlüsse für die Versorgungssteuerung geeignet?
-
Rottenkolber D, Felder S, Schlegel E (2017)
Sozialmedizinische Aspekte von Brustkrebs – ein Literaturreview mit Fokus auf Deutschland
-
Schmitter S, Holzerny P, Brock E, Günzel CA, Ruckdäschel S (2016)
Regulatory Agencies’ Perspective on “Progression-Free Survival” (PFS)
-
The European Journal of Health Economics
Brock E, Braunhofer P, Troxler J, Schneider H (2014)
Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real - life data
-
Navarini A, Laffitteh E, Conrad C, Piffaretti P, Brock E, Ruckdaeschel S, Trüeb R (2010)
Estimation of cost-of-illness in patients with psoriasis in Switzerland
IGES-Group
Since 2012, HealthEcon has been part of the IGES Group—an independent provider of research and consultancy services for the life sciences industry. It covers the entire range of services from market data, regulatory and health technology assessments to analysis of clinical services
As part of the IGES Group, we have been able to expand our capabilities and capacities, particularly in the fields of health services research, clinical research and real-life databases HealthEcon works as an independent entity on the market.
The IGES Institute is the core of the IGES Group. It offers comprehensive services based on expertise: studies, reports, publications, evaluations, concepts and strategies. Since its foundation in 1980, it has conducted over 2,000 research and consulting projects. The IGES Institute is based in Berlin, with additional offices in Nürnberg and Hamburg.
Kontakt
HealthEcon® AG
Steinentorstrasse 19
4051 Basel
Switzerland
+41 (0)61-284 95 60
info@healthecon.com
www.healthecon.com


